Format

Send to

Choose Destination
Caspian J Intern Med. 2017 Fall;8(4):228-238. doi: 10.22088/cjim.8.4.228.

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside.

Author information

1
Department of Cancer Research, Nastaran Center for Cancer Prevention, Mashhad, Iran.
2
Department of Molecular Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
3
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Abstract

Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics medications can also enhance immune-cell activity against tumors. Such medications show great potential in cancer immunotherapy using natural human mechanisms against neoplasms.

KEYWORDS:

Cancer; Gc-MAF; Immunotherapy; Macrophage activating factor; Vitamin D.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center